October 2, 2014
Daiichi Sankyo said on October 1 that it has filed for Japanese regulatory approval of its antibacterial drug Cravit (levofloxacin) for the treatment of pulmonary and other tuberculosis disorders on September 30. The company’s generic arm in Japan, Daiichi Sankyo...read more